

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7832584/publications.pdf>

Version: 2024-02-01

160
papers

46,733
citations

8208

78
h-index

7234

158
g-index

162
all docs

162
docs citations

162
times ranked

51608
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. <i>New England Journal of Medicine</i> , 2001, 344, 783-792.	13.9	10,216
2	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
3	Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	13.9	2,474
4	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
5	A view on drug resistance in cancer. <i>Nature</i> , 2019, 575, 299-309.	13.7	1,391
6	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	1,266
7	The EGF receptor family as targets for cancer therapy. <i>Oncogene</i> , 2000, 19, 6550-6565.	2.6	1,251
8	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640.	6.3	1,165
9	Sequence analysis of mutations and translocations across breast cancer subtypes. <i>Nature</i> , 2012, 486, 405-409.	13.7	1,107
10	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. <i>Nature Reviews Cancer</i> , 2009, 9, 463-475.	12.8	993
11	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. <i>Nature Genetics</i> , 2013, 45, 1439-1445.	9.4	960
12	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	7.7	821
13	Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2445-2459.	0.8	676
14	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	7.7	633
15	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1138-1144.	0.8	593
16	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2630-2637.	0.8	582
17	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017, 21, 374-382.e4.	5.2	578
18	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572

#	ARTICLE	IF	CITATIONS
19	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313.	0.4	509
20	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	7.7	490
21	Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. <i>Nature</i> , 2015, 518, 240-244.	13.7	486
22	Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2005, 23, 5568-5577.	0.8	473
23	Targeting Tyrosine Kinases in Cancer: The Second Wave. <i>Science</i> , 2006, 312, 1175-1178.	6.0	437
24	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	5.1	427
25	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	9.4	411
26	Implementing Genome-Driven Oncology. <i>Cell</i> , 2017, 168, 584-599.	13.5	405
27	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2537.	0.8	381
28	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. <i>Cell</i> , 2016, 167, 260-274.e22.	13.5	376
29	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372
30	Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5323-5333.	0.8	334
31	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	7.7	307
32	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	304
33	Phosphatidylinositol 3-Kinase Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	0.8	298
34	Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor-Positive, First-Line Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3753-3761.	0.8	296
35	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019, 571, 576-579.	13.7	295
36	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. <i>Cancer Discovery</i> , 2017, 7, 277-287.	7.7	286

#	ARTICLE	IF	CITATIONS
37	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	5.8	276
38	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	7.7	275
39	Recurrent and functional regulatory mutations in breast cancer. <i>Nature</i> , 2017, 547, 55-60.	13.7	269
40	AXL Mediates Resistance to PI3K± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2015, 27, 533-546.	7.7	263
41	BRAF Inhibition in <i>BRAF</i> ^{V600} -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	0.8	247
42	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	0.8	240
43	Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. , 1997, 80, 1966-1972.		221
44	Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer. <i>Oncologist</i> , 2011, 16, 12-19.	1.9	221
45	PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. <i>Science</i> , 2017, 355, 1324-1330.	6.0	217
46	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016, 17, 2367-2381.	2.9	215
47	Feedback Suppression of PI3K± Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3K±. <i>Cancer Cell</i> , 2015, 27, 109-122.	7.7	203
48	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
49	First-in-Human Dose Study of the Novel Transforming Growth Factor-Î² Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	3.2	199
50	Adjuvant Trastuzumab: A Milestone in the Treatment of HER2â€“Positive Early Breast Cancer. <i>Oncologist</i> , 2006, 11, 4-12.	1.9	198
51	p95HER2 and Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1515-1519.	0.4	195
52	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K± Inhibition. <i>Cancer Cell</i> , 2016, 30, 229-242.	7.7	187
53	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptorâ€“Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	3.4	187
54	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K± inhibitors. <i>Science</i> , 2019, 366, 714-723.	6.0	185

#	ARTICLE	IF	CITATIONS
55	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	178
56	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	169
57	P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. <i>Science Translational Medicine</i> , 2016, 8, 345ra87.	5.8	152
58	Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1484-1491.	0.8	151
59	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. <i>Molecular and Cellular Biology</i> , 2009, 29, 3319-3331.	1.1	150
60	Somatic <i>PIK3CA</i> mutations as a driver of sporadic venous malformations. <i>Science Translational Medicine</i> , 2016, 8, 332ra42.	5.8	147
61	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	13.7	142
62	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	9.4	140
63	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1589.	3.4	139
64	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. <i>Drug Discovery Today</i> , 2015, 20, 1422-1428.	3.2	136
65	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 102-113.	7.7	136
66	CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 489-491.	1.1	128
67	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2â€™Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
68	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
69	Phase III study of tasisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i>-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA1006-LBA1006.	0.8	116
70	Prospective Blinded Study of <i>BRAF</i>V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	7.7	115
71	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2â€™ advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017, 116, 726-730.	2.9	112
72	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1134-1147.	7.7	106

#	ARTICLE	IF	CITATIONS
73	Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 526-534.	0.8	102
74	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i>TERT</i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. <i>Journal of Pathology</i> , 2016, 238, 508-518.	2.1	102
75	Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 4876-4883.	3.2	99
76	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 244-254.	1.2	96
77	Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1313-1317.	3.2	92
78	Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. <i>Nature Communications</i> , 2017, 8, 14292.	5.8	90
79	Focus on breast cancer. <i>Cancer Cell</i> , 2002, 1, 319-322.	7.7	84
80	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
81	The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. <i>EMBO Journal</i> , 2016, 35, 1902-1922.	3.5	77
82	Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. <i>Cancer Research</i> , 2013, 73, 450-458.	0.4	76
83	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1226-1238.	5.1	76
84	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. <i>Clinical Cancer Research</i> , 2015, 21, 569-576.	3.2	71
85	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating <i>PIK3CA</i> Alterations. <i>Clinical Cancer Research</i> , 2016, 22, 2009-2019.	3.2	70
86	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	7.7	67
87	¹⁸ F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3053-3060.	3.2	66
88	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. <i>Clinical Cancer Research</i> , 2017, 23, 4323-4334.	3.2	64
89	TGF-Î² signalling-related markers in cancer patients with bone metastasis. <i>Biomarkers</i> , 2008, 13, 217-236.	0.9	60
90	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	59

#	ARTICLE	IF	CITATIONS
91	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.4	58
92	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	3.2	54
93	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). <i>Science Signaling</i> , 2018, 11, .	1.6	53
94	Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3030-3035.	3.3	52
95	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133.	0.8	52
96	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018, 103, 147-154.	1.3	52
97	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2462-2470.	3.2	51
98	Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	1.3	51
99	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 49-59.	3.2	49
100	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
101	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387.	3.2	49
102	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. <i>Cell Reports</i> , 2019, 27, 294-306.e5.	2.9	49
103	A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization. <i>Cancer Cell</i> , 2002, 2, 93-95.	7.7	48
104	A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. <i>Cancer Research</i> , 2010, 70, 8537-8546.	0.4	47
105	Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016, 7, 12595.	5.8	45
106	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2 V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	7.7	43
107	Advances in the management of HER2-positive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 113-122.	2.0	42
108	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26.	2.1	37

#	ARTICLE	IF	CITATIONS
109	Effect of p53/HER2/EGFR on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	3.0	36
110	Therapeutic Benefit of Selective Inhibition of p110 α PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2016, 22, 5805-5817.	3.2	35
111	FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. Oncogene, 1998, 17, 761-767.	2.6	31
112	A Pharmacodynamic/Pharmacokinetic Study of Ficlatusumab in Patients with Advanced Solid Tumors and Liver Metastases. Clinical Cancer Research, 2014, 20, 2793-2804.	3.2	31
113	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	2.8	28
114	Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy. Oncologist, 2002, 7, 2-8.	1.9	28
115	Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.. Cancer Research, 2013, 73, LB-64-LB-64.	0.4	26
116	Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. Oncologist, 2001, 6, 26-29.	1.9	25
117	Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy. Cancer, 1993, 71, 2332-2334.	2.0	21
118	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
119	Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. Clinical Cancer Research, 2016, 22, 2099-2101.	3.2	19
120	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	1.2	19
121	The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium. ELife, 2016, 5, e12034.	2.8	19
122	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <i>TP53</i> Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	3.2	18
123	A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, 508-508.	0.8	18
124	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. Methods, 2015, 77-78, 25-30.	1.9	16
125	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	0.6	16
126	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research, 2012, 18, 6364-6372.	3.2	14

#	ARTICLE	IF	CITATIONS
127	Epidermal growth factor receptor pathway inhibitors. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 205-223.	0.5	14
128	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	3.4	13
129	Cell Line-Specific Network Models of ER+ Breast Cancer Identify Potential PI3K Inhibitor Resistance Mechanisms and Drug Combinations. <i>Cancer Research</i> , 2021, 81, 4603-4617.	0.4	13
130	Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor, LY2157299 monohydrate (LY).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2016-2016.	0.8	12
131	A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 51-54.	1.1	11
132	Abstract PD5-5: Phase I study of the PI3K inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer. <i>Cancer Research</i> , 2015, 75, PD5-5-PD5-5.	0.4	11
133	Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 284-285.	4.3	10
134	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87.	2.9	10
135	Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. <i>Cancer Investigation</i> , 1998, 16, 67-71.	0.6	9
136	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2568-2568.	0.8	9
137	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	2.3	9
138	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 346-352.	0.5	7
139	Case 16-2012. <i>New England Journal of Medicine</i> , 2012, 366, 2018-2026.	13.9	6
140	Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1009-1009.	0.8	6
141	Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 174-181.e3.	1.1	5
142	SOLTI NeoPAP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1011-1011.	0.8	5
143	The oral transforming growth factor-beta (TGF- β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2042-2042.	0.8	5
144	Phase Ib combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3118-TPS3118.	0.8	5

#	ARTICLE	IF	CITATIONS
145	SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors.. Journal of Clinical Oncology, 2016, 34, TPS617-TPS617.	0.8	5
146	Creating a stronger front against cancer: ESMO and ECCO join forces. Annals of Oncology, 2008, 19, 1367-1368.	0.6	4
147	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer, 2021, 125, 38-47.	2.9	4
148	Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors. Cancer Research, 2018, 78, CT046-CT046.	0.4	4
149	BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology, 2012, 30, 125-125.	0.8	4
150	Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 558-558.	0.8	4
151	Abstract CT330: Phase I study of PI3K inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Cancer Research, 2015, 75, CT330-CT330.	0.4	3
152	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	0.6	3
153	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology, 2012, 30, 102-102.	0.8	2
154	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 99-99.	0.8	2
155	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 553-553.	0.8	2
156	Reply to S.M. Ali et al. Journal of Clinical Oncology, 2009, 27, e274-e275.	0.8	1
157	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer, 2016, 16, 87-94.	1.1	1
158	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567.	0.8	1
159	Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy. Oncologist, 2001, 6, 26-29.	1.9	1
160	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	0.6	0